Announcements Trials
Browse Landscape

Phase

Phase 2/3 5Phase 1 3Phase 1/2 2Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Thoracic 6Other hematologic neoplasm 6Head & Neck 5Gastrointestinal 5Sarcoma 4Plasma cell 4Gynecologic 3NET 2Myeloid 2Genitourinary 2Endocrine 2CNS 2Other solid neoplasm 1Other neoplasm 1Dermatologic 1

Conditions

Glioblastoma 276Brain Neoplasms 169Glioma 139Central Nervous System Neoplasms 85Gliosarcoma 79Astrocytoma 74Neuroblastoma 64Oligodendroglioma 42Neoplasms 40Breast Neoplasms 38Recurrence 37Carcinoma, Non-Small-Cell Lung 31Medulloblastoma 27Melanoma 26Ovarian Neoplasms 24Lymphoma 21Diffuse Intrinsic Pontine Glioma 21Sarcoma 19Neoplasm Metastasis 19Lung Neoplasms 18Colorectal Neoplasms 17Rhabdomyosarcoma 16Osteosarcoma 16Meningeal Carcinomatosis 15Ependymoma 15Pancreatic Neoplasms 14Meningioma 14Sarcoma, Ewing 13Stomach Neoplasms 12Esophageal Neoplasms 12

Interventions

pamiparib 1Radiation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Histologic Type × CNS × Clear all
NCT07416188 2026-06-05

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
40 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

BeiGene

Phase 1/2 Completed
116 enrolled 31 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡